Assessment and Monitoring Challenges Among Patients With Moderate-to-Severe Atopic Dermatitis Across Fitzpatrick Skin Types: A Photographic Review and Case Series
Valéria Aoki(Universidade de São Paulo), Eric L. Simpson(Oregon Health & Science University), Barry Ladizinski(AbbVie (United States)), Colleen Wegzyn(AbbVie (United States)), Susan Jewell(Netherlands Institute for Radio Astronomy), Seemal R. Desai(The University of Texas Southwestern Medical Center), Marília D. M. Oliveira(Novant Health)
Cited by 7
Related Papers
Two Phase 3 Trials of Dupilumab versus Placebo in Atopic Dermatitis
|New England Journal of Medicine|2016|2k
Tralokinumab for moderate‐to‐severe atopic dermatitis: results from two 52‐week, randomized, double‐blind, multicentre, placebo‐controlled phase III trials (ECZTRA 1 and ECZTRA 2)*
|British Journal of Dermatology|2020|590
Efficacy and safety of crisaborole ointment, a novel, nonsteroidal phosphodiesterase 4 (PDE4) inhibitor for the topical treatment of atopic dermatitis (AD) in children and adults
|Journal of the American Academy of Dermatology|2016|564
Efficacy and Safety of Dupilumab in Adolescents With Uncontrolled Moderate to Severe Atopic Dermatitis
|JAMA Dermatology|2019|505